Genmab A/S (GNMSF)
OTCMKTS · Delayed Price · Currency is USD
316.00
0.00 (0.00%)
Dec 9, 2025, 4:00 PM EST
Genmab Employees
Genmab had 2,682 employees as of December 31, 2024. The number of employees increased by 478 or 21.69% compared to the previous year.
Employees
2,682
Change (1Y)
478
Growth (1Y)
21.69%
Revenue / Employee
$1,434,416
Profits / Employee
$590,552
Market Cap
19.13B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2,682 | 478 | 21.69% |
| Dec 31, 2023 | 2,204 | 544 | 32.77% |
| Dec 31, 2022 | 1,660 | 448 | 36.96% |
| Dec 31, 2021 | 1,212 | 431 | 55.19% |
| Dec 31, 2020 | 781 | 233 | 42.52% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| American Oncology Network | 1,914 |
| Glass House Brands | 374 |
| Silence Therapeutics | 116 |
| Elite Pharmaceuticals | 68 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 13 |
| OpGen | 1 |
Genmab News
- 2 days ago - Genmab (GMAB) Highlights Promising Results from EPCORE CLL-1 Trial - GuruFocus
- 2 days ago - Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT) - Business Wire
- 2 days ago - Genmab : Phase 3 Trial Shows EPKINLY + R2 Cuts Progression Risk By 79% And Achieves 95% ORR In FL - Nasdaq
- 3 days ago - Genmab (GMAB) Reports Positive Phase 3 Study Results for EPKINLY Therapy - GuruFocus
- 3 days ago - Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma - Business Wire
- 4 days ago - Genmab Reports Promising Clinical Trial Results For Fixed-Duration Epcoritamab In Lymphoma - Nasdaq
- 4 days ago - Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL) - Business Wire
- 6 days ago - Genmab A/S at Citi Global Healthcare Conference Transcript - GuruFocus